Aegis Capital Reiterates Buy on Revance Therapeutics (RVNC) Following 4Q Report
Tweet Send to a Friend
Aegis Capital reiterated a Buy rating and $28.00 price target on Revance Therapeutic (NASDAQ: RVNC) following the company's 4Q earnings ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
